Curative Biotechnology Inc
CUBT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CUBT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CUBT
Curative Biotechnology Inc (CUBT) is a development-stage biomedical company focused on acquiring and developing therapeutic and medical device assets, primarily targeting orphan diseases, with a pipeline of pre-clinical programs in rabies, glioblastoma, age-related macular degeneration, and COVID-19 vaccination for kidney failure patients.
Key risk: Going concern uncertainty
Tracking 6 clinical trials · 3 catalysts for Curative Biotechnology Inc.
Curative Biotechnology Inc (CUBT) is a development-stage biomedical company focused on acquiring and developing therapeutic and medical device assets, primarily targeting orphan diseases, with a pipeline of pre-clinical programs in rabies, glioblastoma, age-related macular degeneration, and COVID-19 vaccination for kidney failure patients.
- Curative Biotechnology is a development-stage company that has not yet submitted any INDs to the FDA for its product candidates [sec · filed 2022-11-07].
- The company has licensed four pre-clinical assets focused on rabies, glioblastoma, age-related macular degeneration, and COVID-19 vaccinations in patients with kidney failure [sec · filed 2022-11-07].
- The company has incurred losses since inception and has not demonstrated an ability to generate revenues from the development and sales of its proposed therapeutic products [sec · filed 2022-04-15].
- There is substantial doubt about the company's ability to continue as a going concern [sec · filed 2024-05-06].
- The company estimates it will need approximately $38 million and two years to reach inflection points in its current programs [sec · filed 2022-11-07].
What works
- The company focuses on acquiring assets with accelerated clinical or regulatory development paths, which could reduce time to market [sec · filed 2022-11-07].
- Management targets programs that can create material inflection points within a two-year window, potentially enabling earlier partnering or licensing [sec · filed 2024-05-06].
- The company leverages management's experience and relationships in the life science community to acquire therapeutic candidates at appropriate valuations [sec · filed 2024-05-06].
What to weigh
- The company has not submitted any INDs to the FDA and all assets are pre-clinical, indicating a very early stage of development [sec · filed 2022-11-07].
- There is substantial doubt about the company's ability to continue as a going concern, and it has relied entirely on debt and equity financings to fund operations [sec · filed 2024-05-06].
- The company will require substantial additional capital in the near future, and there is no assurance it can obtain financing on acceptable terms [sec · filed 2024-05-06].
- The company has incurred losses since inception and has not demonstrated an ability to generate revenues from its proposed products [sec · filed 2022-04-15].
From the filings
Quoted directly from source documents.
The company has not submitted any INDs to the FDA for any product candidates.
“As of the date of this prospectus, we have not submitted any INDs with the FDA for any of our product candidates.”
SEC filings · November 7, 2022
There is substantial doubt about the company's ability to continue as a going concern.
“there continues to be substantial doubt as to our ability to continue as a going concern.”
SEC filings · May 6, 2024
The company has incurred losses since inception and has not demonstrated revenue generation.
“We have incurred losses since our inception and have not demonstrated an ability to generate revenues from the development and sales of our proposed therapeutic products.”
SEC filings · April 15, 2022
The company estimates it needs $38 million and two years to reach inflection points.
“We anticipate that we will need approximately $38 million and a period of two (2) years to reach inflection points in all current indications underlying programs that we are actively pursuing.”
SEC filings · November 7, 2022
Catalyst timeline
- 2030-12-31 · Patent_Expiry · SIVEXTRO — Patent/exclusivity expiry for SIVEXTRO; may open market opportunities for generic or alternative products.
- 2034-05-28 · Patent_Expiry · DIFICID — Patent/exclusivity expiry for DIFICID; potential for competitive entry.
- 2035-08-14 · Patent_Expiry · ZERBAXA — Patent/exclusivity expiry for ZERBAXA; may affect market dynamics.
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — There is substantial doubt about the company's ability to continue as a going concern [sec · filed 2024-05-06].
- No FDA submissions yet
- Dependence on future financing — The company has no revenue and relies entirely on debt/equity financings; additional capital may not be available [sec · filed 2024-05-06].
- Early-stage pipeline risk — All programs are pre-clinical; drug development is highly uncertain and may fail [sec · filed 2022-04-15].
What to watch
- Ability to raise additional capital to fund operations and pre-clinical development [sec · filed 2024-05-06].
- Progress toward filing an IND with the FDA for any of the four licensed programs [sec · filed 2022-11-07].
- Any partnering, licensing, or sale of programs as inflection points are reached [sec · filed 2022-11-07].
- Patent expiry catalysts for SIVEXTRO (2030-12-31), DIFICID (2034-05-28), and ZERBAXA (2035-08-14) [upcoming catalysts].
Sources: SEC filings · Generated August 30, 2026 · How we verify sources →
Run Curative Biotechnology Inc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Curative Biotechnology Inc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Catalysts
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for Curative Biotechnology Inc?
Curative Biotechnology Inc (CUBT) is a development-stage biomedical company focused on acquiring and developing therapeutic and medical device assets, primarily targeting orphan diseases, with a pipeline of pre-clinical programs in rabies, glioblastoma, age-related macular degeneration, and COVID-19 vaccination for kidney failure patients.
What is Curative Biotechnology Inc's next catalyst?
Curative Biotechnology Inc's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: SIVEXTRO" — expected December 31, 2030.
Who is the CEO of Curative Biotechnology Inc?
Mr. I. Richard Garr Esq., J.D. is the chief executive officer of Curative Biotechnology Inc (CUBT).
Where is Curative Biotechnology Inc headquartered?
Curative Biotechnology Inc (CUBT) is headquartered in Palm Beach Gardens, FL, United States.
What therapeutic areas does Curative Biotechnology Inc focus on?
Curative Biotechnology Inc develops therapies across Oncology, Infectious Disease, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.